Large patient populations
Chronic itch and related skin and mucosal conditions affect large patient populations and represent substantial therapeutic markets.
Neuroimmune therapeutics
A new approach
to persistent
symptoms.
Orinda Therapeutics is developing a new class of neuroimmune-modulating therapeutics, starting with chronic itch. Our goal is to address significant unmet needs in large patient populations.
Explore our approachThe neuro-gating concept
Sensory signalingINPUT
Neuro-gating through sensory-neuron biology
Modulated responseRESEARCH GOAL
Conceptual illustration. Not experimental data.
Development priority: chronic itchLicensing opportunity: chronic cough
01 / Our approach
Targeting the connection between sensation and inflammation.
Our approach centers on neuro-gating: modulating sensory-neuron signaling with the aim of reducing persistent symptoms.
We are developing locally delivered therapeutics and exploring a potential family of anti-inflammatory compounds. Chronic itch is our development priority, with broader potential across skin and mucosal conditions.
Significant unmet need
Existing treatments can leave patients with incomplete relief or tolerability limitations. Our goal is to expand their therapeutic options.
A differentiated approach
Neuro-gating offers a distinct direction for therapeutic development, grounded in sensory-neuron biology.
02 / Therapeutic focus
Chronic itch first.
Selective partnerships.
We are concentrating our development efforts on chronic itch and seeking licensing partners to advance chronic cough.
Chronic itch
Development priorityDeveloping locally delivered therapeutics to address persistent itch and substantial unmet need in dermatology.
Rhinitis
Potential applicationExploring sensory modulation for persistent nasal symptoms in a large therapeutic market.
Chronic cough
Licensing opportunitySeeking a licensing partner to lead development and commercialization for chronic cough.
Broader research interests include other skin and mucosal conditions.
03 / Leadership
Industry experience.
Academic depth.
Decades of complementary experience.
Our founders combine pharmaceutical and biotechnology industry experience with academic research in sensory neuroscience and pharmacology.
Their backgrounds in drug development, pharmaceutical sciences, and company building connect scientific discovery with therapeutic development.
Investor & licensing inquiries
Let’s start a conversation.
Connect with Orinda about our chronic itch development strategy and chronic cough licensing opportunity.